FDA approval was definitive - new product increased revenue sp flies.
Vax result, good but not definitive - there is no increased revenue. it is actually an ongoing cost.
VAX needs - definitive results or a partner to sign up for the sp to fly.
While these results would be of interest, I don't think this it's enough to grab a partner. They will be waiting for the final numbers next year, just like Ian Frazer.
Let Frazer finish doing his thing, company can continue to focus on costs and sales. Its a numbers game for the next few quarters.
Ann: HSV-2 Interim Results Announcement-AHZ.AX, page-79
-
- There are more pages in this discussion • 153 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.39 |
Change
-0.040(0.35%) |
Mkt cap ! $239.5M | |||
| Open | High | Low | Value | Volume |
| $11.45 | $11.50 | $11.33 | $53.97K | 4.705K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 739 | $11.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.49 | 406 | 2 |
View Market Depth
| Last trade - 11.52am 15/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |